Analytical Data
-
Gene name
SETDB1
- Application
-
Alternative Names
ERG-associated protein with SET domain
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15047
-
Expression Region
1-397aa
-
Molecular Weight
71.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SETDB1, or SET domain bifunctional 1, is a lysine methyltransferase that plays a crucial role in epigenetic regulation through the methylation of histone H3 at lysine 9 (H3K9me), an important modification associated with gene repression and chromatin condensation. Research surrounding SETDB1 has gained prominence due to its implications in various biological processes, including development, cell differentiation, and stem cell maintenance. Abnormal expression or mutations in SETDB1 have been linked to several diseases, particularly cancers, where altered epigenetic landscapes can lead to tumorigenesis. Furthermore, SETDB1 is instrumental in the formation of heterochromatin and has been identified as a key player in ecological adaptations and immune responses. The recombinant protein studies of SETDB1 are essential for elucidating its molecular mechanisms, functional interactions, and regulatory networks. Investigating SETDB1's structure-function relationships can provide insights into its enzymatic activity and how it contributes to chromatin remodeling. By producing and characterizing SETDB1 as a recombinant protein, researchers aim to explore its biochemical properties, substrate specificity, and potential as a therapeutic target in epigenetic therapies. Overall, the study of SETDB1 and its recombinant form offers a promising avenue for understanding epigenetic regulation in health and disease, potentially paving the way for novel intervention strategies in cancer and other disorders linked to dysregulated gene expression.
